

OMTN, Volume 17

## **Supplemental Information**


**Use of Heterologous Vesiculovirus G Proteins**

**Circumvents the Humoral Anti-envelope Immunity**

**in Lentivector-Based *In Vivo* Gene Delivery**

**Altar M. Munis, Giada Mattiuzzo, Emma M. Bentley, Mary K. Collins, James E. Eyles, and Yasuhiro Takeuchi**

## SUPPLEMENTARY FIGURES



**Supplementary Figure S1: Titers and Luciferase Activity of the LVs Used.** qPCR and flow cytometry-based titers and luciferase activity of the vectors used in the **(A)** initial VSVind.G-LV challenge and **(B)** VesG-LV challenge studies.

```

VSVind/1-511      1 --MKCLLYLAFIFGVNCKFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTAIQVKMPKSHKAIQADGWM 74
MARAV/1-512      1 --MLR LFLFCFLALGAHSAKFTIVFPHHQKGNWKNVPSSTYHYCPSSSDQNWHNDLIGVSLHVKKIPKSHKAIQADGWM 74
COCV/1-512      1 -MNFLLLT FIVLPLCSHAKFSIVFPQSQKGNWKNVPSSTYHYCPSSSDQNWHNDLIGITMKVKMPKTHKAIQADGWM 75
PIRYV/1-529      1 MDLFPILLVVVLMTDTVLGKFKQIVFEPDQNELEWRPVMVGDSTRHCQSS EMQFDGGSRSQTILITGKAPVGITPSKSDGFI 76

VSVind/1-511      75 CHASKWVTTCDFRWYGPKYITQSIRSFTPSV EQCKESI EQTKQGTWLNPGFPPQSCGYATVTD AEAVIVQVTPHHV 150
MARAV/1-512      75 CHAAKWVTTCDFRWYGPKYITHS IHSMSPTLEQCKTSIEQTKQGVWLNPGFPPQSCGYATVTD AEVAVVQATPHHV 150
COCV/1-512      76 CHAAKWITTCDFRWYGPKYITHS IHSIQPTS EQCKESI KQTKQGTWMSPGFPPQSCGYATVTD SVAVVQATPHHV 151
PIRYV/1-529      77 CHAAKWVTTCDFRWYGPKYITHS IHLRPTSDCETALQRYKDGSLINLGFPPESCGYATVTDSEAMLVQVTPHHV 152

VSVind/1-511      151 LVDEYTG EWVDSQFINGKCSNYI CPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSEDEGELS LSGKEGTGFRSNYF 226
MARAV/1-512      151 LVDEYTG EWIDSQLVGGKCSKEV CQTVHNSTVWHADYKITGLCESNLASVDITFFSEDEGQKTS LGKPNTGFRSNHF 226
COCV/1-512      152 LVDEYTG EWIDSQLFPNGKCEEE CQTVHNSTVWYSYDYKVTGLCDATLVDT EITFFSEDEGKES I GKPNTGYRSNYF 227
PIRYV/1-529      153 GVDDYR GHWIDPLFPGGECSTNFCQTVHNSTVWYIPKSKQKTDICQASFKNIKMTASY--PS EGALVSDRFAHSHAYH 226

VSVind/1-511      227 AYETGGKACKMQYCKHWGVRLPSGVWFEMADKDL----FAAARFPECPEGSSISAPSQTSVDVSLIQDVERILDYS 298
MARAV/1-512      227 AYESGEKACRMQYCTQWGI RLPSPGVWFELVDKDL----FQAAKLPECPRGSSISAPSQTSVDVSLIQDVERILDYS 298
COCV/1-512      228 AYEKGDKVKCMNYCKHAGVRLPSGVWFEFVDQDV----YAAAKLPECPRVGTISAPTQTSVDVSLIQDVERILDYS 299
PIRYV/1-529      227 PNMPGSTVCIIMDFCEQKGLRFTNGEWMGLNVEQSI REKKISAIFPNVAGTEIRATLES EGARTLTWETQRMLDYS 302


VSVind/1-511      299 LCQETWSKIRAGLPI SPVDLSYLAPKNPGTGPAFTIINGTLKYFETRYIRVDIAAPILSRMVGMIS-GTTTERELW 373
MARAV/1-512      299 LCQETWSKIRAKLPVSPVDLSYLAPKNPSTGPAFTIINGTLKYFETRYIRVDISNPIIPHMVGTMS-GTTTERELW 373
COCV/1-512      300 LCQETWSKIRSKQPVSPVDLSYLAPKNPSTGPAFTIINGTLKYFETRYIRIDINPIISKMVGKIS-GSQTERELW 374
PIRYV/1-529      303 LCQNTWDKVS RKEPLSPLDLSYLSRAPKGMAYTVINGTLHSAHAKYIRTWIDY GEMKEIKGGRGEYSKAPELLW 378

VSVind/1-511      374 DDWAPYEDVEIGPNGVLRITSSGYKFPLYMIGHGMLSDSLHLS SKAQVFEHPHIQDAASQLPDDLES LFFGDTGLSKN 449
MARAV/1-512      374 NDWYPYEDVEIGPNGVLRITPTGFKFPLYMIGHGMLSDSLHKS SQAQVFEHPHAKDAASQLPDDLET LFFGDTGLSKN 449
COCV/1-512      375 TEWFPYEGVEIGPNGILKTPYGYKFLPMIGHGMLSDSLHKT SQAQVFEHPHLAEAPKQLPEEETLFFGDTGLSKN 450
PIRYV/1-529      379 SQWDFDGPFKIGPNGLRLHTGKTFKFLYLVGAGITIDEDLHELDEAAPIDHPQMPDAKSVLPEDEEILFFGDTGVSKN 454

VSVind/1-511      450 PIELVEGWFSWSSKSSIASFFFIIIGLIIGLFLVLRVGIHLICIKLKHKKRQIYTDIEMN-----RLGK---- 511
MARAV/1-512      450 PVELVEGWFSWSSKSTLASFFLIIGLGVALIFIRIIVAIRYKGRKTQKIYNDVEMS-----RLGNK---- 512
COCV/1-512      451 PVELIEGWFSWSSKSTVVTFFFAIGVFI LLYVVARIVIAVRYRQGSNNKRIYNDIEMS-----RFRK---- 512
PIRYV/1-529      455 PIELIQGWFSNWRRESVMAIVGIVLVLLIVVTFLAIKTVRVLNCLWRPRKKRIVRQEWVDESRLNHFERMRGFPPEYVKR 529

```

**Supplementary Figure S2: Multiple Amino Acid Sequence Alignment of the G proteins of Vesiculoviruses.** The sequences of vesiculoviruses (VSVind, UniProt: P03522; MARAV, UniProt: F8SPF4; COCV, UniProt: O56677; PIRYV, UniProt: Q85213) were aligned using ClustalOmega online multiple sequence alignment tool (EMBL-EPI), and the alignments were visualized using JalView software.<sup>1</sup> Dashed lines represent gaps introduced to maximize matching of amino acid residues. Blue shading indicates percent identity; dark blue: 80-100%, medium blue: 60-80% light blue: 40-60%, and no colour indicating <40% identity.



**Supplementary Figure S3: Fitted Curves of the Neutralizations Assays Used to Calculate IC50 Values.**

## REFERENCES

1. Waterhouse, AM, Procter, JB, Martin, DMA, Clamp, M, and Barton, GJ (2009). Jalview Version 2-a multiple sequence alignment editor and analysis workbench. *Bioinformatics* **25**: 1189-1191.